

Resource Summary Report

Generated by [kravitz2](#) on Aug 16, 2026

Alexa Fluor(R) 700 anti-human CD3

RRID:AB_2563408

Type: Antibody

Proper Citation

BioLegend Cat# 317340, RRID:AB_2563408

Antibody Information

URL: http://antibodyregistry.org/AB_2563408

Proper Citation: BioLegend Cat# 317340, RRID:AB_2563408

Target Antigen: CD3

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Alexa Fluor(R) 700 anti-human CD3

Description: This monoclonal targets CD3

Target Organism: human

Clone ID: Clone OKT3

Antibody ID: AB_2563408

Vendor: BioLegend

Catalog Number: 317340

Alternative Catalog Numbers: 317339

Record Creation Time: 20250819T210738+0000

Record Last Update: 20250819T215604+0000

Ratings and Alerts

No rating or validation information has been found for Alexa Fluor(R) 700 anti-human CD3.

No alerts have been found for Alexa Fluor(R) 700 anti-human CD3.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 21 mentions in open access literature.

Listed below are recent publications. The full list is available at [kravitz2](#) .

Jassowicz L, et al. (2026) Dissecting the cellular architecture of breast cancer brain metastases reveals prognostically distinct immune landscapes. *Cancer cell*, 44(6), 1290.

Cheng BY, et al. (2026) Pharmacologic glycoengineering of Fc γ receptor IIIa enhances force-resistant IgG-Fc γ R interactions and anti-tumor antibody efficacy. *Immunity*, 59(7), 2030.

Tripathi A, et al. (2026) Protocol for intranuclear Nrf2 detection in activated mouse, human, and Jurkat T cells by spectral flow cytometry. *STAR protocols*, 7(1), 104360.

Nathan N, et al. (2026) Tumor-draining lymph nodes in ovarian cancer lack germinal centers but harbor tumor-reactive memory B cells clonally linked to intra-tumoral B cells. *Immunity*, 59(6), 1743.

Tripathi A, et al. (2026) Ciclopirox reprograms effector responses and modulates Notch1 activation in activated human T cells. *iScience*, 29(6), 116079.

Rodriguez C, et al. (2026) A radiopharmaceutical enhances CAR T cells against radio-sensitive and radio-resistant neuroblastoma by tumor sensitization and TME remodeling. *Cell reports. Medicine*, 7(7), 102884.

Li Q, et al. (2025) Targeting proBDNF in neutrophil subsets: Sepsis biomarker discovery and insights into mitochondrial hyperactivation. *iScience*, 28(11), 113642.

Edalat SG, et al. (2024) Molecular maps of synovial cells in inflammatory arthritis using an optimized synovial tissue dissociation protocol. *iScience*, 27(6), 109707.

Ritchlin CT, et al. (2024) Psoriatic arthritis subtypes are phenocopied in humanized mice. *JCI insight*, 9(15).

Lê H, et al. (2023) In vitro vascularized immunocompetent patient-derived model to test cancer therapies. *iScience*, 26(10), 108094.

Chen H, et al. (2023) EBV-Upregulated B7-H3 Inhibits NK cell-Mediated Antitumor Function and Contributes to Nasopharyngeal Carcinoma Progression. *Cancer immunology*

research, 11(6), 830.

Ciacchi L, et al. (2023) CD4+ T cell-mediated recognition of a conserved cholesterol-dependent cytolysin epitope generates broad antibacterial immunity. *Immunity*, 56(5), 1082.

Wilson AS, et al. (2022) Neutrophil extracellular traps and their histones promote Th17 cell differentiation directly via TLR2. *Nature communications*, 13(1), 528.

Zhao X, et al. (2022) In vivo G-CSF treatment activates the GR-SOCS1 axis to suppress IFN- γ secretion by natural killer cells. *Cell reports*, 40(11), 111342.

Fendler A, et al. (2022) Functional immune responses against SARS-CoV-2 variants of concern after fourth COVID-19 vaccine dose or infection in patients with blood cancer. *Cell reports. Medicine*, 3(10), 100781.

Salomé B, et al. (2022) NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancer. *Cancer cell*, 40(9), 1027.

Tarke A, et al. (2021) Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals. *Cell reports. Medicine*, 2(7), 100355.

Carbonneau S, et al. (2021) An IMiD-inducible degron provides reversible regulation for chimeric antigen receptor expression and activity. *Cell chemical biology*, 28(6), 802.

Tarke A, et al. (2021) Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases. *Cell reports. Medicine*, 2(2), 100204.

Grifoni A, et al. (2020) Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. *Cell*, 181(7), 1489.